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Abstract
Objective: The objective of this selective EBM review is to determine whether or not there is
efficacy with combination treatment benzoyl peroxide and clindamycin for progressive macular
hypomelanosis in adults.
Study Design: A review of three English language studies. One published in 2006 and two in
2011. Includes two RCT’s and one randomized left-right comparison study.
Data Sources: Researched articles via PubMed and Cochrane database. All articles were
published in peer-reviewed journals. Two randomized, controlled trials and one randomized leftright comparison study were used.
Outcomes Measured: The outcomes measured by: subjective patient ratings based on
photographs before and after treatment and two dermatologists’ ratings. Relyveld et al study and
Sim et al study in addition used a color analyzer.
Results: The two randomized, controlled trials and the left-right comparison study showed that
the use of clindamycin and benzoyl peroxide was effective in the treatment of progressive
macular hypomelonosis in adults. Results from these three studies showed Improvement of the
overall PMH lesions by the investigator, patient, dermatologist and color analyzer (quantitatively
compares discoloration, erythema, pigmentation and skin color).
Conclusions: The results of the randomized, controlled trials and left-right comparison study
indicate that combination products clindamycin and benzoyl peroxide are effective in the
treatment of progressive macular hypomelonosis. All three studies also demonstrated that
benzoyl peroxide and clindamycin were safe when used to treat PMH.
.
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Introduction
Progressive macular hypomelanosis (PMH) is a dermatosis characterized by nummular,
hypopigmented, symmetric, asymptomatic macules of unclear etiology which affect the front and
back of the trunk and are confluent around the midline.3 The lesions are not preceded by
inflammatory disease and tend to increase progressively in number. Histopathologically, the skin
lesions show a decrease in melanin content in the epidermis compared with the adjacent skin
without lesions. No other abnormalities are seen in the epidermis or dermis such as spongiosis or
other signs of eczematous inflammation.4 There is no consensus or first-line therapy in the
treatment of PMH and the treatment options used are very little effective.3
PMH has been reported in patients with skin type’s I-III.2 It occurs in all races and has a
worldwide distribution, but it is more frequently identified in young adults/women and African
American people from tropical countries, but the prevalence studies are scarce.3 In 1994, Lesueur
et al diagnosed 121 cases of PMH during a screening for leprosy among 511 patients in the
French West Indies (Martinique). Also in Martinique, Guillet et al diagnosed 150 new cases in
their dermatology clinic.2 PMH can cause cosmetic problems for patients, which can lead to a
negative impact on the patient’s quality of life. Since, this condition is frequently misdiagnosed;
no exact percentage is given to determine how much money is spent annually.1 However, due to
the numerous individuals affected by progressive macular hypomelanosis, this condition is
commonly encountered in the scope of PA practice. Therefore, it is important to be able to
correctly diagnose and treat PMH.
The diagnosis is clinical and the main differential diagnosis is pityriasis versicolor.3 To
differentiate pityriasis versicolor from PMH potassium hydroxide test results of epidermal
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scrapings are performed.2 The clinical findings of PMH include the presence of red follicular
fluorescence in the hypopigmented spots when illuminated with a wood’s lamp in a dark room.2
Unfortunately, little is known about the origin and pathogenesis of PMH. 2 One thought is
the presence of propionibacterium acnes (P. acnes) in the hypopigmented macules playing an
important role in the development of PMH. Similar to the Malassezia species in tines versicolor,
it is possible that P. acnes produces a depigmenting factor that disrupts melanogenesis and
induces hypopigmented lesions. Since a bacteria may contribute to the cause of PMH it makes
sense that antimicrobial therapy would be used for the treatment of PMH and has been associated
with clinical improvement.4
Numerous therapy options have been used with variable results for the treatment of PMH,
including local hydration, sun exposure with UVA/UVB, phototherapy, topical corticosteroids
and oral tetracycline. However, there is no first-line medication or consensus in the treatment of
this dermatosis and the treatment options used have shown to be not very effective. However, the
combination of benzoyl peroxide 5% and clindamycin 1% has shown to be quite effective
against P. acnes as previously mentioned. The combined use of both of these products reduces
the risk of development of resistant P. acnes. Elimination of P. acnes with a topical antimicrobial
therapy could therefore improve repigmentation in patients with PMH.3
Objective
“The objective of this selective EBM review is to determine whether or not there is
efficacy with combination treatment benzoyl peroxide and clindamycin for progressive macular
hypomelanosis in adults.”

Colosi, Benzoyl Peroxide & Clindamycin PMH, 3

Methods
The population in these studies consisted of healthy men and women over the age of
twenty-one with a diagnosis of PMH. The interventions used were 5% benzoyl peroxide and 1%
clindamycin. The treatment groups receiving benzoyl peroxide and clindamycin were compared
to those receiving either UVA/fluticasone 0.05%, gel placebo, or narrow band ultraviolet B
(NBUVB). The outcomes measured were those of patient-oriented evidence. There was
improvement of the overall PMH lesions by the investigator, patient, dermatologist and color
analyzer (quantitatively compares erythema, pigmentation and skin color). This review includes
two randomized control trials and one randomized left-right comparison study.
The three studies in this review were researched using PubMed and Cochrane database
by the author. Keywords used in literature search were “progressive macular hypomelanosis”,
“clindamycin”, and “benzoyl peroxide”. All articles were published in English in peer-reviewed
journals. One article was published in 2006 and the other two articles in 2011. Articles were
selected by the author based on their relevance and outcome to the patient. All three reviews had
similar inclusion and exclusion criteria. The Inclusion criteria were healthy men and women over
21 years old with a diagnosis of PMH. The exclusion criteria were pregnant or lactating females,
allergies to products given or history of pityriasis versicolor. Table 1 demonstrates the
demographics of the studies included. Statistics included in the studies were relative benefit
increase (RBI), absolute benefit increase (ABI), relative risk increase (RRI), absolute risk
increase (ARI), number needed to treat (NNT), number needed to harm (NNH), and p-values.
Table 1: Table of demographics and characteristics of included studies
Study

Type

Relyveld
2006 (2)

RCT

#
Age
Pts (yrs)
45 1655

Inclusion
Criteria
Ages 16-55
with

Exclusion
Criteria
Positive
potassium

W/D

Interventions

7

Benzoyl
peroxide 5%
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diagnosis of
PMH

Santos, RCT (double 23
2011 (3) blind

>15

placebo
controlled)

>15, clinical
diagnosis of
PMH
confirmed by
two
dermatologists

Randomized
Sim,
2011 (4) left-right
comparison
study

10

2143

, negative
mycological
examination
& no
previous
treatment for
30 days
Ages 21-43,
with a
diagnosis of
PMH

hydroxide test
results;
sensitive to any
of the study
medication
ingredients,
pregnant or
lactating
Pregnant or
lactating
females,
patients with
associated
disease &
patients allergic
to the therapy
drugs used in
this study or
sensitive to
sunlight

hydrogel &
clindamycin 1%
lotion & UVA
VS. Fluticasone
& UVA

0

History of
3
pityriasis
versicolor or
other
inflammatory
disorders in the
hypopigmented
spot, sensitive
to any
ingredients of
the study
medications or
sunlight, treated
with other
treatments,
pregnant or
lactating
females

Benzoyl
peroxide 5% &
Clindamycin
1% VS.
Visually
matched
placebo

NBUVB with
benzoyl
peroxide &
clindamycin VS.

NBUVB
monotherapy

Outcomes Measured
Outcomes measured were those of patient-oriented evidence that matters. All three
articles measured the efficacy of repigmentation/decrease incidence of hypopigmentation of
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PMH by subjective patient ratings (based on photographs taken before and after treatment) and
by two dermatologists. The differences between these studies are the Relyveld et al study also
measured the skin with a color analyzer at baseline; after 2, 6, 10, and 14 weeks of treatment;
and after a period of 12 weeks without treatment (26 weeks). This color analyzer transforms a
reflectance spectrum R (λ) into 3 values: L∗, a∗, and b∗. L∗ represents the lightness of the
spectrum and varies from 0 for a black object to 100 for a white object, a∗ represents green
(negative values) and red (positive values), and b∗ represents blue (negative values) and yellow
(positive values).2 Santos et al measured efficacy on photographs, but they were taken on day’s
0, 15, 60 and 90. The following scale of clinical improvement was previously established based
on the area of repigmentation: no improvement, little improvement, partial improvement,
significant improvement, and complete recovery.3 Lastly, Sim et al study in addition to using the
photographs, also used the color analyzer. This study rated the efficacy of repigmentation on a
score from 0-4; 0-5%, no change; 1, 6-25% repigmentation; 2, 26-50% repigmentation; 3, 5175% repigmentation; 4, 76-100% repigmentation.4
Another outcome measured was adverse events of benzoyl peroxide and clindamycin.
This was evaluated by the side effects and physical examination findings. Though there were
some effects documented, this never deterred patients from using the medication or caused them
to not follow-up.
Results
This EBM review was done on two randomized controlled trials and one randomized leftright comparison study. The results of the two randomized controlled trials were presented as
dichotomous data; therefore, I will display the results of those two studies together in Tables 2
& 3 and the left-right comparison study separate. Data from the two dichotomous studies were

Colosi, Benzoyl Peroxide & Clindamycin PMH, 6

analyzed with the intention to treat.
In the Relyveld et al study, after fourteen weeks of treatment, both the treated sides
became darker than normal skin, but this effect was more pronounced on the bcUVA (benzoyl
peroxide/clindamycin + UVA) side. After twelve weeks without treatment, the antibacterial
(bcUVA)-treated side had the same degree of pigmentation as normal skin whereas the antiinflammatory fUVA (fluticasone + UVA)-treated side was lighter than normal skin. Although
the skin on the bcUVA side remained evenly pigmented, hypopigmentation macules reappeared
on the fUVA side. The patients and dermatologists scored the bcUVA-treated side higher than
the fUVA-treated side. This difference was highly significant after fourteen weeks of treatment
(P < .0001 for patients, P < .0001 for dermatologists). At the end of the follow-up, 62% of the
patients judged their bcUVA-treated side as totally repigmented, but only 13% of the patients
gave such a score to their fUVA-treated side (P < .0001). The dermatologists scored 62% of the
bcUVA-treated sides and 22% of fUVA-treated sides as totally repigmented at the end of the
follow-up (P < .0001). Most adverse effects were mild and followed anticipated patterns. More
patients reported cutaneous side effects with antibacterial than with corticosteroid therapy (71%
vs. 24%, P < .0001). The incidence of side effects decreased after the second week of both
treatments. After the sixth week, only four (9%) patients mentioned side effects on the bcUVA
side and three (7%) patients mentioned side effects on the fUVA side.2 Unfortunately, the study
did not list what the exact side effects were, therefore, it is not documented in this paper.
In the Santos et al study patients were divided into two groups. Group A used the topical
combination of benzoyl peroxide 5% and clindamycin 1% and group B used gel cream as
placebo. Patients were advised to expose themselves to the sun on daily basis and were
systematically evaluated and photographed. The collected data was entered and analyzed. A p
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value < 0.05 was considered statistically significant. Eleven patients (85%) in group A showed
significant improvement of lesions and only two patients (20%) in group B showed equivalent
clinical improvement, with a statistically significant difference between the two groups, p =
0.003. Seven patients, (53%) in group A, showed complete recovery of lesions 90 days after
beginning the therapy and only two patients (20%) in group B were cured at the same time
interval. Thirteen patients (56%) had at least one side effect during treatment, eleven (85%)
patients from group A, and two (15%) from group B, with a statistically significant difference
between the two groups (p = 0.003). The clinical side effects reported were pruritus (50%),
stinging (40%), erythema (30%), desquamation (22%), burning sensation (22%), xeroderma
(8%) and plaques (4%). The side effects were well tolerated by all patients and there was no loss
in terms of follow-up.3 Table 2 shows the efficacy of benzoyl peroxide 5% and clindamycin 1%
in the treatment of progressive macular hypomelanosis in the two studies just discussed. Table 3
shows the incidence of side effects in patients treated with benzoyl peroxide and clindamycin
versus the control fUVA for Relyveld et al study or placebo for Santos et al study.
Table 2 Clinical efficacy of benzoyl peroxide and clindamycin in the treatment of PMH
Study

CER
(fUVA) for
Relyveld,
(placebo) for
Santos

EER
benzoyl
peroxide 5%
+
clindamycin
1%

p-value

RBI

ABI

NNT

Relyveld,
2006
Santos, 2011

22%

62%

P < .0001

180%

40%

3

20%

85%

P < 0.003

330%

65%

2

CER – control event rate, EER – experimental event rate, RBI – relative benefit increase,
ABI – absolute benefit increase, NNT – number needed to treat
Table 3 Incidence of side effects in patients treated with benzoyl peroxide & clindamycin vs. control
Study

CER (fUVA)
for Relyveld,
(placebo) for

EER
benzoyl
peroxide 5% +

RRI

ARI

NNH
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Relyveld, 2006

Santos
24%

clindamycin 1%
71%

200%

47%

3

Santos, 2011

15%

85%

470%

70%

2

EER – experimental event rate, CER – control event rate, RRI – relative risk increase,
ARI – absolute risk increase, NNH – number needed to harm
Lastly, I will discuss the Sim et al study which since it was not presented in dichotomous
data; I will discuss the results narratively. After 8 weeks of treatment, significant repigmentation
appeared at both of the treated sides compared with the initial evaluation. The mean difference in
L values between the skin lesions and adjacent skin without lesions was 4.52 ± 1.65 at the initial
evaluation and was reduced significantly to 0.94 ± 0.65 during the treatment period in the combNBUVB area (benzoyl peroxide & clindamycin + UVB), and in the mono-NBUVB (UVB) area,
it was 4.34 ± 1.39 and 1.18 ± 0.94 respectively (P < 0.05). However, there were no significant
differences between each treated site at both of the evaluation points in time. At 6 months after
treatment, clinical improvement remained in four of seven patients; however, almost recurrence
occurred in the other patients. The mean difference in L values between the skin lesions and
adjacent skin without lesions was 1.86 ± 1.42 in the comb-NBUVB area and 2.05 ± 1.55 in the
mono-NBUVB area, and this difference was not statistically significant. There were minimal
side effects in this study. Five patients complained of transient irritation and two patients
complained of erythematous skin eruption in the comb-NBUVB area and this resolved following
daily application of anti-microbial gel. All adverse effects were mild and resolved with topical
corticosteroid therapy.4
Discussion
In the Relyveld et al study, antibacterial therapy with UVA was more effective than antiinflammatory therapy with UVA in the treatment of PMH. Anti-bacterial therapy led to better
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repigmentation as indicated by darker objective skin measurements and, more importantly, by
higher score for treatment success by both patients and dermatologists.2 One limitation to this
study or a recommendation I would suggest for the future would be a more thorough
investigation on the medicines used. This study did not explore the optimal dose for benzoyl
peroxide and clindamycin, other routes of administration, or whether other types of antibiotics
are equally effective.
In the Santos et al study, the use of topical combination of benzoyl peroxide 5% and
clindamycin 1% showed improvement in PMH. Patient adherence to regular sun exposure was
similar between the two groups, which excludes the possibility of solar radiation being the main
factor responsible for treatment success. The choice of the antimicrobial was due to the fact that
combination of benzoyl peroxide 5% and clindamycin 1% are very effective against P. acne,
easy to apply and has few systemic side effects. The main limitations of this study were small
sample size and absence of confirmation of P. acnes. P. acnes was not objectively demonstrated
in the lesions, but the significant clinical improvement of the group treated with benzoyl
peroxide 5% and clindamycin 1% suggests colonization and supports the hypothesis that
colonization by P. acnes may be involved in the pathogenesis of PMH.3
In the Sim et al study the comb-NBUVB treatment was not superior to mono-NBUVB
treatment in patients with PMH. Even though both treatments showed improvement in
repigmentation after eight weeks, there was no significant difference to determine which
treatment was more effective. At the six month follow-up recurrence occurred in some
participants. Even though recurrence occurred in some patients, NBUVB combined with benzoyl
peroxide and clindamycin appears to be a safe and useful modality for the treatment of PMH.
One limitation was the study did not have enough statistical power to support the equivalent
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clinical results between the treated sites at both evaluation points in time because of the small
number of enrolled patients. Therefore, further investigation with a larger number would be
needed for relevant results.4
Conclusion
The trials reviewed imply that benzoyl peroxide 5% and clindamycin 1% is safe and
effective for the treatment of progressive macular hypomelanosis. Patients in all three studies
showed improvement in their PMH when applying topical benzoyl peroxide and clindamycin. It
was also suggested from these studies that benzoyl peroxide and clindamycin are well-tolerated,
as it does not cause significant adverse events. Benzoyl peroxide and clindamycin combination
treatment provides a new treatment option for medical providers and those diagnosed with PMH.
Although these studies do conclude the use of benzoyl peroxide and clindamycin are safe and
effective, more trials should be done to assess the safety of using these two treatment options
over a chronic time period, such as: exploring the optimal dose for benzoyl peroxide and
clindamycin, other routes of administration or whether other types of antibiotics are equally
effective. Regardless of the need for additional studies, benzoyl peroxide and clindamycin is a
safe and effective way of treating progressive macular hypomelanosis.
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